Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Predicting response to epigenetic therapy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Breaking down brain barrier breaches in cerebral malaria

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Neutrophil extracellular traps - the dark side of neutrophils

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Blodsygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

View graph of relations

Drugs targeting the epigenome are new promising cancer treatment modalities; however, not all patients receive the same benefit from these drugs. In contrast to conventional chemotherapy, responses may take several months after the initiation of treatment to occur. Accordingly, identification of good pretreatment predictors of response is of great value. Many clinical parameters and molecular targets have been tested in preclinical and clinical studies with varying results, leaving room for optimization. Here we provide an overview of markers that may predict the efficacy of FDA- and EMA-approved epigenetic drugs.

Original languageEnglish
JournalThe Journal of clinical investigation
Volume124
Issue number1
Pages (from-to)47-55
Number of pages9
ISSN0021-9738
DOIs
Publication statusPublished - Jan 2014

    Research areas

  • Antineoplastic Agents, DNA Methylation, Drug Resistance, Neoplasm, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Histone Deacetylase Inhibitors, Humans, Molecular Targeted Therapy, Neoplasms, Prognosis, Treatment Outcome, Tumor Markers, Biological

ID: 45023751